key: cord-0819447-0sj3oqiy
authors: Ching, Krystal L.; de Vries, Maren; Gago, Juan; Dancel-Manning, Kristen; Sall, Joseph; Rice, William J.; Barnett, Clea; Liang, Feng-Xia; Thorpe, Lorna E.; Shopsin, Bo; Segal, Leopoldo N.; Dittmann, Meike; Torres, Victor J.; Cadwell, Ken
title: ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection
date: 2021-12-23
journal: bioRxiv
DOI: 10.1101/2021.12.17.473223
sha: 949c3135fcb7a23c59cd7150a69f90ff70ac628c
doc_id: 819447
cord_uid: 0sj3oqiy

Extracellular vesicles of endosomal origin, exosomes, mediate intercellular communication by transporting substrates with a variety of functions related to tissue homeostasis and disease. Their diagnostic and therapeutic potential has been recognized for diseases such as cancer in which signaling defects are prominent. However, it is unclear to what extent exosomes and their cargo inform the progression of infectious diseases. We recently defined a subset of exosomes termed defensosomes that are mobilized during bacterial infection in a manner dependent on autophagy proteins. Through incorporating protein receptors on their surface, defensosomes mediated host defense by binding and inhibiting pore-forming toxins secreted by bacterial pathogens. Given this capacity to serve as decoys that interfere with surface protein interactions, we investigated the role of defensosomes during infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19. Consistent with a protective function, exosomes containing high levels of the viral receptor ACE2 in bronchioalveolar lavage fluid from critically ill COVID-19 patients was associated with reduced ICU and hospitalization times. We found ACE2+ exosomes were induced by SARS-CoV-2 infection and activation of viral sensors in cell culture, which required the autophagy protein ATG16L1, defining these as defensosomes. We further demonstrate that ACE2+ defensosomes directly bind and block viral entry. These findings suggest that defensosomes may contribute to the antiviral response against SARS-CoV-2 and expand our knowledge on the regulation and effects of extracellular vesicles during infection.

Exosomes are a subgroup of single membraned vesicles 40-120 nm in diameter secreted by virtually every cell type. Cargo molecules ranging from non-coding RNAs to proteins involved in signal transduction are incorporated during exosome biogenesis, which involves exocytosis of endosomal structures [1] . As such, exosomes mediate intercellular communication events involved in cell proliferation, migration, and cancer [2] .

A role in host defense is supported by the finding that exosomes can deliver nucleic acids and other immunogenic moieties from infected cells that elicit interferon responses or promote antigen presentation by target cells [3] [4] [5] [6] [7] [8] . However, how exosomes are regulated in response to infections remains unclear. A better understanding may inform strategies that seek to use extracellular vesicles as biomarkers or therapeutic agents for infectious disease.

In our previous work, we identified exosomes involved in host defense termed defensosomes that mediated protection against bacterial pore-forming toxins that kill target cells, such as α-toxin produced by Staphylococcus aureus [9] . Recognition of bacterial DNA by toll-like receptor 9 (TLR9) led to increased production of defensosomes decorated by ADAM10, the host cell surface target of α-toxin, in a manner dependent on ATG16L1 and other components of the membrane trafficking pathway of autophagy. We further demonstrated that ADAM10 + defensosomes serve as decoys that bind α-toxin and prevent cytotoxicity in cell culture and animal models [9] . Therefore, in addition to mediating intercellular communication by transferring signaling molecules between cells, exosomes can also promote host defense through a surface interaction with bacterial proteins. Whether defensosomes are deployed during a viral infection remains unclear.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the respiratory virus responsible for the ongoing global COVID-19 pandemic, can cause life threatening tissue injury to the lung as well as extrapulmonary symptoms that are less understood [10] . Entry into host cells mainly depends on the binding of receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to host receptor ACE2. The affinity of SARS-CoV-2 spike for ACE2 is 5 times higher than that of SARS-CoV spike [11] , and 1,000 times higher than hemagglutinin of Influenza A for sialic acid [12] . Given this dependence on a high affinity cell surface interaction for viral entry, we hypothesized ACE2 containing defensosomes would inhibit SARS-CoV-2 infection through the binding of the spike protein.

Few studies, if any, have analyzed exosomes in mucosal tissues of patients during an ongoing infection. This is especially true in the setting of SARS-CoV-2 infection where access to lower airway samples were limited due to concerns about possible risks for health care professionals [13] [14] [15] [16] [17] [18] [19] [20] . In the airways, ACE2 expression exists as a gradient, with the highest levels in the nasal passageway, down to the lower airways where it is exclusively expressed on Type II pneumocytes [21] . To determine whether ACE2+ exosomes are generated and are present in the respiratory tract, we analyzed bronchioalveolar lavage fluid (BALF) samples from 80 critically ill COVID-19 patients [22] using biochemical fractionation to enrich for exosomes followed by flow cytometry [9] . All patients in our cohort were admitted to the intensive care unit (ICU) due to respiratory failure requiring invasive mechanical ventilation and tested positive for SARS-CoV-2 infection [22] . Applying stringent gating criteria for exosomes, we observed remarkable interindividual variation in the proportion of exosomes with surface ACE2 and the levels of ACE2 present on each exosome measured by mean fluorescence intensity (MFI) (Fig.   1A , Supp. Fig. 1A -C). We found that 10 patients had at least two-fold higher exosomes levels in their BALF compared to the mean exosome levels from the other patients. These data suggest that there is variation between individuals in how much ACE2 is loaded into each exosome as well as how many ACE2+ exosomes are produced by each person.

We then asked whether level of ACE2 on exosomes or proportion of ACE2+ exosomes correlate with clinical parameters such as patient age, sex, disease severity, infection status, and other comorbidities linked to SARS-CoV-2 infection such as diabetes or hypertension. 76.2% of the patients were male, mostly nonwhite (53.8%), with a mean age of 62 years (SD, 14.2). Hypertension and diabetes were reported in 52.5% and 38.3% of patients, respectively (Supp. Table 1 ). Two patients were excluded from analysis because they were not within 3 standard deviations from the mean (47.96 days) for length of stay in the ICU. As a sensitivity analysis, we also ran the regressions using ACE2 MFI as a predictor of ICU stay outcome, resulting in the same trends in the covariates (Supp. Table 3 ). Compiling the information regarding the proportion of exosomes that contain ACE2+ in patient BALF, we ran different models using clinical data to test whether there was any association with ACE2+ exosomes and length of stay in the ICU, as there was no correlation with mortality. We performed a linear model and a negative binomial model to test this relationship, and we controlled for age, gender, culture results of BAL and blood, diabetes, and hypertension. We also included in a sensitivity analysis model an interaction term between gender, sex, and hypertension, as they are usually correlated.

We expressed the coefficients without interactions for simplicity because the estimates did not significantly change. The linear model resulted in negative correlation between length of stay in the ICU and the proportion of ACE2+ exosomes found in the BALF (Table   1 , Fig. 1B) . The negative binomial model predicted similar results (Supp. Table 2 ). To account for increased length of stay in the ICU due to complications or subsequent infections, we also used ventilation days as an outcome, and found that proportion of ACE2+ exosomes remained a significant predictor (Supp. Tables 4-5).

These analyses uncovered a threshold where patients with a proportion of ACE2+ exosomes lower than the mean (38.78%) generally have increased lengths of stay in both the ICU and hospital, and increased days on a ventilator (Fig. 1D, Supp. Fig. 1D ). Individuals with diabetes (or both diabetes and hypertension) clustered below the average proportion of ACE2+ exosomes (Fig. 1D ), suggesting common comorbidities may influence the proportion of ACE2+ exosomes. Individuals with hypertension have been shown to have reduced levels of circulating ACE2 with the adverse consequence of increased concentration of the vasoconstricting molecule Angiotensin II due to activation of ACE [23] . However, neither diabetes nor hypertension were associated with statistically significant differences in ACE2 levels on exosomes (Supp. Fig. 1E-F) . Altogether, these data show that the proportion of ACE2+ exosomes and level of ACE2 on individual exosomes in BALF from patients with COVID-19 are highly variable, and their increased presence are associated with a reduction in the hospitalization days.

We previously showed that exosomes are induced by TLR9 activation in response to bacterial DNA or synthetic agonist CpG-A. It was unclear whether innate immune ligands generated during RNA viral infections affect exosome production. Although SARS-CoV-2 is not predicted to directly activate DNA sensors, damage during respiratory tract infection can lead to production of oxidized mitochondrial DNA (ox-mtDNA) [24, 25] , which is known to be a potent ligand for TLR9 [26] . Stimulation with ox-mtDNA increased exosome production in A549 cells, but this was not observed with sheared genomic DNA (gDNA) or DNA fragments without any oxidized bases ( Fig. 2A) . We also tested CpG-B, which can activate TLR9, but unlike CpG-A, lacks a phosphodiester backbone and poorly induces interferons (IFNs) [27] . CpG-B stimulation failed to elicit exosomes from A549 cells (Fig. 2B ). SARS-CoV-2 has been shown to indirectly activate the cytosolic DNA sensing pathway dependent on cGAS/STING [28] . However, ligands for cGAS/STING (2'3'-cGAMP and 3'3'-cGAMP) failed to induce exosomes (Fig. 2B ).

It is possible that IFNs generated downstream of TLR9 activation mediate exosome production. Stimulation of A549 cells with IFN-β induced exosomes in a concentration dependent manner, where at higher concentrations, the number of exosomes began to decrease (Fig. 2C) , which may be due to ISGylation and degradation of the compartment where exosomes are generated [29] . IFN-α and IFN-λ2 also induced exosomes ( Fig. 2D -E). As expected, IFN-β failed to elicit exosomes from triple-knockout (TKO) A549 cells that lack receptors necessary for recognition of all three major classes of IFNs (IFNAR, IFNGR, and IFNLR) (Fig. 2F ). In contrast, TKO A549 cells were still able to produce exosomes in response to CpG-A (Fig. 2G) . Thus, IFN stimulation is sufficient to induce exosome production, but are not required downstream of nucleic acid sensing.

SARS-CoV-2 infection generate viral ssRNA and dsRNA that may serve as signals to induce exosomes. When transfected into cells, low and high molecular weight versions of the dsRNA mimetic poly I:C preferentially activate the cytosolic RNA sensors RIG-I and MDA-5, respectively, but we found that neither induced exosomes (Fig. 2H . In A549 cells, the endosomal dsRNA sensor TLR3 is expressed at low levels; IFN-α treatment induces TLR3 to functionally active levels, allowing A549 cells to become sensitive to untransfected poly I:C [30] . Following pretreatment with IFNα for 24hr, A549 cells produced 10-20-fold more exosomes in response to poly I:C without a transfection agent ( Fig. 2I ). A549 cells do not express the endosomal ssRNA sensors TLR7 or TLR8. We found that ectopic expression of TLR7 led to exosome induction upon stimulation with a synthetic agonist, R848 (Fig. 2J ).

Given that multiple innate immune ligands induce exosome production, we asked whether ACE2+ exosomes are induced by SARS-CoV-2 infection. We found that SARS-CoV-2 infection of A549 cells ectopically expressing ACE2 (A549 ACE2+ ) induced robust production of ACE2+ exosomes (Fig. 2K ). Similar to our observations with bacteria, SARS-CoV-2-induced exosome production was impaired by ATG16L1 knockdown (Fig.   2K ). Therefore, the enhanced production of ACE2+ exosomes display a key hallmark of defensosomesinduced in response to infectious cues in a manner dependent on ATG16L1.

Our finding that ACE2+ exosomes in patient BALF display an inverse correlation with length of hospital stay raised the possibility that they play a role during viral infection akin to our previous description of defensosomes during bacterial toxinosis. Therefore, we tested whether addition of exosomes can protect Vero E6 cells, which are highly susceptible to SARS-CoV-2 infection (Fig. 3A ). Exosomes were isolated from A549 ACE2+ cells (Fig. 3B ) and mixed with human SARS-CoV-2 USA WA1/2020 isolate at an MOI of 0.01. We included a polyclonal neutralizing antibody targeting spike (nAb) as a positive control. Addition of ACE2+ exosomes led to a dose-dependent reduction in viral nucleoprotein (NP) staining by immunofluorescence microscopy at 24 hr post-infection ( Fig. 3C -D, Supp. Fig. 2A) , whereas ACE2-exosomes from untransduced control A549s failed to inhibit infection. Also, addition of the microvesicle fraction that does not contain exosomes (5000xg) did not decrease infection levels (Fig. 3C) . We also tested neutralization in human airway epithelial cultures (HAECs), an air-liquid (ALI) interface model that contains all major cell types found in the bronchial epithelium (basal, ciliated, secretory), organized in pseudostratified architecture [31] . Addition of ACE2+ exosomes mixed with SARS-CoV-2 to the apical side ("lumen") blocked infection of HAECs, while ACE2-exosomes did not show any significant effect (Fig. 3E, Supp. Fig. 2B ).

We next tested whether inducing exosome production protects against viral infection without the need of adding exogenous exosomes from donor cells. We found that pretreatment with CpG-A, which we confirmed induces exosome production by Vero E6 cells in a manner dependent on ATG16L1 (Fig. 3F-G) , led to a reduction in cells infected with SARS-CoV-2 (Fig. 3H ). Removing the exosome-containing supernatant prior to infection led to similar levels of SARS-CoV-2 infection as unstimulated cells (Fig. 3H, Supp. Fig.   2C ). This protection is unlikely to be mediated by IFNs, as Vero E6 cells cannot produce IFNs [32, 33] . Together, these results show that defensosomes can inhibit SARS-CoV-2 infection.

We next used electron microscopy techniques to visualize the interactions between SARS-CoV-2 virions and defensosomes. Viral particles with predicted spherical shape and uniform size of 80-100 nm in diameter were detected by negative stain imaging in control suspensions containing SARS-CoV-2 virions alone ( Fig. 4A ) [34] . With the addition of exosomes, we detected structures with the characteristic collapsed morphology of exosomes clustered around particles with virion morphology. The difficulty in distinguishing exosomes and virions due to their similar shape and size precluded quantification of the data. Therefore, we used immuno-gold labeling in which exosomes and SARS-CoV-2 virions were identified by an anti-CD63 antibody coupled to 18 nm gold particle and an anti-NP antibody coupled to a nanogold particle (1.4 nm), respectively ( Fig   4B) . We observed an enrichment of CD63 labeling around SARS-CoV-2 virions when incubated with ACE2+ exosomes, but not ACE2-exosomes (Fig. 4C ). The pronounced clustering of CD63 in the ACE2+ exosome-virus mixtures may be indicative of multiple exosomes bound to the virions, however, we cannot definitively conclude the number of exosomes due to the lack of contrast of the exosome membranes.

Lastly, we applied cryo-electron microscopy and tomography to confirm these associations between SARS-CoV-2 virions and ACE2+ exosomes. Virions were easily distinguished by the presence of protrusions that resembled the club-like head of the spike protein and exosomes were larger single membraned vesicles, spherical or ellipsoid in shape. Focusing on the area between the viral and exosome membranes, we were able to visualize an elongated structure resembling the post-fusion form of spike and ACE2 in some tomograms (Supp. Fig. 3A , 3B, Videos 1-2). Tomographic reconstruction also captured several virions around larger exosomes as well as potential virions inside an exosome (Video 3). Collectively, these data demonstrate that the presence of ACE2 on exosomes increases binding and clustering of virions.

Our analyses of an inpatient cohort of COVID-19 patients revealed ACE2 levels on exosomes in BALF can display striking interindividual variability, and that a high proportion of ACE2+ exosomes, especially those with increased surface levels, are associated with reduced hospital stay. Although it is unclear whether ACE2+ exosomes are a marker or have a causative role in recovery from SARS-CoV-2 infection, our cell culture experiments indicate that they can inhibit viral infection by serving as defensosomes. The ability to produce sufficient numbers of defensosomes is key to providing optimal protection in vitro, and thus, understanding the factors that contribute to variable exosome production at mucosal surfaces during SARS-CoV-2 infection and other conditions will be of great interest. Transcriptional regulation and cleavage by proteases such as ADAM10 and ADAM17 [35] may also explain heterogeneity in ACE2+ exosomes. Other unanswered questions include how ACE2+ exosome release affects the availability of ACE2 in the tissue and whether this impacts acute injury to the lung, another function of this critical enzyme involved in cardiovascular processes [36] . Also, we focused on surface protein interactions, but it is important to consider other ways SARS-CoV-2 infection can be impacted by exosomes, which have been shown to facilitate the transfer of viral and cellular components to target cells with either pro-viral or antiviral consequences depending on the pathogen [37] [38] [39] .

Infection by SARS-CoV-2 and other coronaviruses leads to formation of structures resembling autophagosomes [40] [41] [42] , double-membrane vesicles generated during autophagy that target intracellular material to the lysosome for degradation [43] . Several SARS-CoV-2 proteins inhibit formation of autophagosomes or prevent the acidification of lysosomes and endosomes, promoting viral egress from the cell [44] [45] [46] [47] [48] [49] . Although viruses such as SARS-CoV-2 evade autophagy-mediated degradation during intracellular replication, our results suggest extracellular virions may be subject to neutralization by defensosomes generated through an autophagy-like process dependent on ATG16L1. In this context, it is notable that defensosomes are induced by innate immune activation of TLRs that require a signaling endosome [50, 51] , which may coincide with the location from which exosomes are generated. The termination of TLR7 signaling is mediated by the packaging of TLR7 into exosomes via a ESCRT independent mechanism involving ALIX and the recruitment of syntenin-1 by UNC93B1 [52] , providing precedence for coupling viral RNA recognition with extracellular vesicle trafficking. Cells that produce significant amounts of IFN in response to sensing of viral PAMPs through TLRs, such as plasmacytoid dendritic cells [53] , could play an important role in initiating early protection by activating cells in distal tissues to release exosomes.

Several clinical trials are underway for exosome-based therapies against various cancers and kidney disease [54] [55] [56] . The advantage of strategies involving exosomes includes their scalability, stability in biofluids, and ability to be engineered to carry desired receptors and even deliver drugs. Our results support a broad innate antimicrobial function for defensosomes that includes defense against viral disease. An improved understanding of defensosome regulation may inform clinical applications. 

The characteristics of this cohort have recently been described [22] . Briefly, we enrolled adults (>18 years old) admitted to the intensive care unit due to respiratory failure requiring invasive mechanical ventilation with confirmed diagnosis of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR). Lower airway samples (bronchoalveolar lavage, BAL) were obtained during clinically indicated bronchoscopy performed for airway clearance or for percutaneous tracheostomy placement. Surviving subjects signed informed consent to participate in this study while samples and metadata from subjects who died or were incapacitated were de-identified and included in this study. All patients or their legal representative agreed to participate via our NYU IRB approved protocol (IRB no. s16-00122/01598). The study protocol was approved by the Institutional Review Board of New York University.

A549 cells were purchased from ATCC. A549 ACE2 cells were generated using lentiviral transduction of a human ACE2 cDNA expressing plasmid (backbone: pLV-EF1a-IRES-Puro (Addgene 85132) as previously described [31] . TLR7+ A549 were generated by lentiviral transduction of pcDNA3-TLR7-YFP (a gift from Doug Golenbock (Addgene plasmid # 13022; http://n2t.net/addgene:13022 ; RRID:Addgene_13022)). A549 ACE2 cells were selected using 1μg/ml puromycin. Cells were cultured with 10% Dulbecco's modified Eagle medium (DMEM (Gibco), 10% fetal calf serum (FCS), 1% non-essential amino acids (NEAA), 1% Penicillin/Streptomycin) and filtered using a 0.22μm filter unit (Millipore Images were analyzed and quantified with HCS Navigator software.

Maintenance of HAECs were done as described in [31] . At 

Lentivirus based knockdown of human ATG16L1 (5'-ACTGTAGCTTTGCCGTGAATG-3') was performed using MISSION shRNA constructs (Sigma-Aldrich) and psPAX2

packaging system. psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260).

Lentivirus expressing shRNAs were produced by DNA transfection using Lipofectamine 3000 (Thermo Fisher). Transduction was performed using Polybrene (Millipore) and selection was done using 1μg/mL puromycin.

Exosomes pellets were stained with 100μl of an antibody cocktail in 1X PBS (Corning)

containing anti-CD9 (human HI9a, mouse MZ3), anti-CD63 (human H5C6, mouse NVG-2), anti-CD81 antibodies (human 5a6, mouse Eat-2) from Biolegend, and anti-human ACE2 (R&D Biosystems cat no. FABAF9332R) at 1:100 for 1hr at 4°C, rocking.

Exosomes were stained with PKH67 cell linker dye (Sigma). Exosomes were washed with 1X PBS once and ultracentrifuged at 100,000xg for 1.5hr. The exosome pellet was resuspended in PBS. Cells and exosomes were analyzed using a Beckman Coulter Cytoflex S cytometer at the slowest flow rate.

Cell culture supernatants were spun at 500xg for 10min, followed by a 10,000xg spin for 10min. Supernatants were passed through a 0.22μm filter (Millex-GP PES). Supernatants were washed with 1x PBS and pelleted by ultracentrifugation at 100,000xg for 1.5hrs.

Exosomes used for neutralization were resuspended in viral media (10% DMEM, 1%

HEPES, 1% PenStrep) and transferred to a non-TC round bottom 96-well plate (Corning).

All human BAL samples were processed into cellular and supernatant fractions before freezing for further analysis. Exosomes were isolated from 200μl of thawed acellular BAL fluid and fixed to a final concentration of 4% PFA before being removed from the BSL-3 facility. Samples were washed with PBS and ultracentrifuged at 100,000xg for 1.5hr before staining for flow cytometry analysis.

Exosomes isolated from A549 and A549 ACE2 cells stimulated with Bafilomycin A1 were mixed with SARS-CoV-2 and allowed to bind for 1hr at 37°C in the BSL3 before being fixed with 4% PFA. Suspensions of SARS-CoV-2/exosomes were ultracentrifuged once at 100,000 x g to pellet, and then resuspended in PBS before processing for TEM imaging. Grids were washed with PBS and then incubated in PBS/50mM glycine for 3min to quench the unbounded aldehyde group. The grids were incubated with anti-NP antibody

(1:100) in perm buffer for 1.5 hr followed by anti-mouse Fab' nanogold (1:250, Nanoprobe, New York) in perm buffer for 30min. Grids were fixed in 1% glutaraldehyde in PBS for 5min, washed with distilled water, followed by washes with 0.02M sodium citrate buffer (pH 7.0). The silver enhancement is done using HQ Silver enhancement kit (#2012, HQ Silver, Nanoprobe, New York) for 9 minutes, and rinsed with ddH2O. Finally, grids were contrasted with 3% uranyl acetate and embedded with 2% methylcellulose in a ratio of 1 to 9.

Immunogold and nanogold double labeling was quantified using ImageJ software (NIH).

Samples for CryoET were plunge frozen in liquid ethane with a VitroBot Mark IV (Thermo Fisher) at 20°C at 100% humidity on C-flat (Protochips, Morrisville NC) 1.2/1.3 grids with 80s easyGlow (Ted Pella Inc, Redding CA) glow discharge. All images were acquired on the Talos Arctica (Thermo Fisher) housed at NYU. Images were taken at 200 kV with a Gatan K3 imaging system (Gatan Inc, Pleasanton CA) collected at 28,000X nominal magnification. The calibrated super-resolution pixel size of 0.7040 Å was used for processing.

Micrographs were collected using Leginon [58, 59] at a dose rate of 11.21 e -/Å 2 /s with a total exposure of 3.50 seconds, for an accumulated dose of 39.23 e -/Å 2 . Intermediate frames were recorded every 0.07 seconds for a total of 50 frames per micrograph. Frames were aligned using Motioncor2 [60] .

Tilt series were collected using SerialEM [61] at a dose rate of 11.21 e -/Å 2 /s with a total exposure of 0.25 second for an accumulated dose of 2.79 e -/Å 2 per tilted image.

Intermediate frames were recorded every 0.05 seconds for a total of 5 frames per micrograph. Movies were collected in super-resolution mode. Tilt series were acquired in a bidirectional pattern starting from -18°, with a range from -60° to 60° in 3° step with a total dose of 114e -/Å 2 .

Frames were aligned using Warp [62] , binned to the physical pixel size of 1.408 Å, and constructed into a tilt series stack for further processing. Micrographs within each tilt series were aligned with EMAN2 [63] and constructed into a tomogram at binning 4 (5.63 Å/pixel) using Fourier inversion. Tomograms were denoised using Topaz [64] . Denoised tomograms were inspected using IMOD [65] and clipped to appropriate size. Movies were made from selected tomograms using ImageJ. Automated segmentation was performed using EMAN2 to segment membranes, and further 3D rendering and refinement of Spike proteins was done manually on ORS Dragonfly (Object Research Systems, Quebec, Canada).

Anonymized data contained patient demographics, medications prescribed during hospital admission, vitals upon entry to the hospital, reported comorbidities, spike and RBD antibody titers, and blood and lung culture results. All analyses were performed in R Studio (version 1.4.1717).

Statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software, San Diego, California USA; https://www.graphpad.com/). All graphs show the mean and standard error of the mean (SEM). An unpaired two-tailed t-test was used to evaluate differences between two groups with Welch's correction. One way ANOVA with Dunnett's post-test was used to evaluate experiments involving groups of 3 or more. Two-way ANOVA with Dunnett's or Šidák's post-test was used to evaluate groups with more than one variable. Correlation was analyzed using Pearson r. For each test, a p-value <0.05 is considered statistically significant. Clinical data was analyzed using R-studio. We performed descriptive analysis extracting data from EHR for these patients and 

Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication

The biology, function, and biomedical applications of exosomes

Extracellular vesicles deliver Mycobacterium RNA to promote host immunity and bacterial killing

Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling

Malaria parasite DNA-harbouring vesicles activate cytosolic immune sensors

Exosomes function in antigen presentation during an in vivo Mycobacterium tuberculosis infection

MHC class Imediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells

Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo

Decoy exosomes provide protection against bacterial toxins

Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Receptor binding by a ferret-transmissible H5 avian influenza virus

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases

Wuhan outbreak

Tracheostomy guidance during the COVID-19 Pandemic

Tracheostomy in the COVID-19 era: global and multidisciplinary guidance

Performing tracheostomy during the Covid-19 pandemic: guidance and recommendations from the Critical Care and Acute Care Surgery Committees of the American Association for the Surgery of Trauma

Tracheotomy recommendations during the COVID-19 pandemic. American Association of Otolaryngology-Head and Neck Surgery

Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019

Tracheostomy Considerations during the COVID-19 Pandemic

Recommendations from the CSO-HNS taskforce on performance of tracheotomy during the COVID-19 pandemic

SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract

Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome

The role of ACE2 in cardiovascular physiology

Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19

Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality

Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus

Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB

ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins

IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression

A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19

Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)

Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia

Angiotensin-converting enzyme 2 protects from severe acute lung failure

The role of extracellular vesicles in COVID-19 virus infection

Cells infected with herpes simplex virus 1 export to uninfected cells exosomes containing STING, viral mRNAs, and microRNAs

Circulating and exosome-packaged hepatitis C single-stranded RNA induce monocyte differentiation via TLR7/8 to polarized macrophages and fibrocytes

SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography

Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication

Coronavirus replication complex formation utilizes components of cellular autophagy

Autophagy in major human diseases

β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway

Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities

ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress

Mammalian hybrid pre-autophagosomal structure HyPAS generates autophagosomes

The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

Signaling from endosomes: location makes a difference

UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity

Production of type I interferons: plasmacytoid dendritic cells and beyond

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer

Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases

Comparative Analysis of Six IRF Family Members in Alveolar Epithelial Cell-Intrinsic Antiviral Responses

New features and applications

Automated molecular microscopy: the new Leginon system

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Automated electron microscope tomography using robust prediction of specimen movements

Real-time cryo-electron microscopy data preprocessing with Warp

Single particle tomography in EMAN2

Positiveunlabeled convolutional neural networks for particle picking in cryo-electron micrographs

Automated tilt series alignment and tomographic reconstruction in IMOD

in the ICU. As a sensitivity analysis, we also performed a negative binomial model. with ACE2 MFI as a predictor instead of % ACE2 positivity, which yielded the same results.